These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
554 related items for PubMed ID: 18816698
1. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Griffin TC, Weitzman S, Weinstein H, Chang M, Cairo M, Hutchison R, Shiramizu B, Wiley J, Woods D, Barnich M, Gross TG, Children's Oncology Group. Pediatr Blood Cancer; 2009 Feb; 52(2):177-81. PubMed ID: 18816698 [Abstract] [Full Text] [Related]
2. Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival. Shea TC, Beaven AW, Moore DT, Serody JS, Gabriel DA, Chao N, Gockerman JP, Garcia RA, Rizzieri DA. Leuk Lymphoma; 2009 May; 50(5):741-8. PubMed ID: 19358012 [Abstract] [Full Text] [Related]
3. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Abali H, Urün Y, Oksüzoğlu B, Budakoğlu B, Yildirim N, Güler T, Ozet G, Zengin N. Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961 [Abstract] [Full Text] [Related]
4. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy. Mappa S, Marturano E, Licata G, Frezzato M, Frungillo N, Ilariucci F, Stelitano C, Ferrari A, Sorarù M, Vianello F, Baldini L, Proserpio I, Foppoli M, Assanelli A, Reni M, Caligaris-Cappio F, Ferreri AJ. Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567 [Abstract] [Full Text] [Related]
5. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, O'Connor O, Filippa DA, Teruya-Feldstein J, Gencarelli A, Qin J, Waxman A, Yahalom J, Moskowitz CH. Blood; 2004 May 15; 103(10):3684-8. PubMed ID: 14739217 [Abstract] [Full Text] [Related]
8. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB. Cancer Chemother Pharmacol; 2002 May 15; 49 Suppl 1():S13-20. PubMed ID: 12042984 [Abstract] [Full Text] [Related]
9. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Hagberg H, Gisselbrecht C, CORAL study group. Ann Oncol; 2006 May 15; 17 Suppl 4():iv31-2. PubMed ID: 16702182 [Abstract] [Full Text] [Related]
15. Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature. Kushner BH, Modak S, Kramer K, Basu EM, Roberts SS, Cheung NK. Cancer; 2013 Feb 01; 119(3):665-71. PubMed ID: 22951749 [Abstract] [Full Text] [Related]
17. Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant. Joyce RM, Kraser CN, Tetrealt JC, Giallombardo N, McDermott D, Levine J, Umiel T, Regan M, Hurley D, Uhl L, Avigan D. Eur J Haematol Suppl; 2001 Jul 01; 64():56-62. PubMed ID: 11486404 [Abstract] [Full Text] [Related]
18. Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%. Mohamedbhai SG, Sibson K, Marafioti T, Kayani I, Lowry L, Goldstone AH, Linch DC, Ardeshna KM. Br J Haematol; 2011 Jan 01; 152(2):175-81. PubMed ID: 21092025 [Abstract] [Full Text] [Related]